Highlights of This Issue 4303

SPECIAL FEATURES 4305

Food and Oral Antineoplastics: More Than Meets the Eye
Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko
See article p. 4446

Personalized Tamoxifen: A Step Closer but Miles To Go
Aditya Bardia and Vered Stearns
See article p. 4468

Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia
Dennis J. Gousetis and Leonidas C. Platanias
See article p. 4382

New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts
Donghui Li and James L. Abbruzzese

Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka, Takahito Hara, and Masami Kusaka

PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang and Dihua Yu

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilano, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F
Windy Berkofsky-Fessler, Monica Buzzai, Marianne K-H. Kim, Steven Fruchman, Vesna Najfeld, Dong-Joon Min, Fabricio F. Costa, Jared M. Bishof, Marcelo B. Soares, Melanie Jane McConnell, WeiJia Zhang, Ross Levine, D. Gary Gilliland, Raffaele Calogero, and Jonathan D. Licht

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara De Brouwer, Katiene De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmin Hoebeeck, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, HuiB Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman

Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
4374 | The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group

4382 | Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation
Javier Redondo-Muñoz, Elizabeth Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo
See commentary p. 4311

4392 | Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines
Haishan Xu and Geoffrey W. Krystal

4401 | Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer
Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaïd, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez

4411 | Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma
Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsu-Hueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

4421 | Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study
Martin Lauss, Markus Ringnér, and Mattias Höglund

4432 | Preclinical and Clinical Evidence that Deoxy-2-[¹⁸F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

4441 | Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
Soonmo Peter Kang and Mark J. Ratain
See commentary p. 4305

4452 | Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture
ABOUT THE COVER

This is an original study providing, from preclinical models to patients, a reliable proof of \(^{18}\)FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an \(^{18}\)FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor \(^{18}\)FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.